Choroidal vascularity index can reveal treatment response and disease activity among patients with chronic CSCR undergoing PDT treatment.
The FDA has approved Ozempic (semaglutide) to reduce the risk of kidney disease worsening and cardiovascular death in those with T2D and CKD.
Chronic kidney disease (CKD) is a growing global health concern, significantly contributing to morbidity and mortality rates worldwide. Characterized by a ...
The FDA’s approval of Ozempic to battle chronic kidney disease “allows us to more broadly address conditions within cardiovascular-kidney-metabolic syndrome, which affects millions of ...
The FDA has approved popular antiobesity drug Ozempic to help protect patients with type 2 diabetes from kidney disease.
The approval is based on results from the Phase III FLOW trial demonstrating Ozempic reduced the risk of severe kidney outcomes by 24% compared to placebo, including kidney failure, reduction in ...
Hosted on MSN1d
Ozempic receives FDA nod for treating chronic kidney disease; experts explain how diabetes drug reduces CKD riskThe US Food and Drug Administration (FDA) approval is based on the clinical trials that showed how Ozempic, the diabetes drug ...
Statins, a class of cholesterol-lowering drugs, have no effect on kidney function, a research team led by the University of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback